1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search
results consecutively by pressing the navigational buttons
(
<
1 of
10
>).
Within the text the search
result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
[...] Research and development –297.4 –287.3 –917.6 –916.0 –3.9 –4.5 –12.3 –13.9 Operating result (EBIT)1 274.5 152.3 752.2 327.8 21.1 8.2 51.0 24.4 Depreciation and amortization 190.6 219.8 606.6 663.6 1.9 2.9 6.7 8.8 Impairment losses 14.7 10.5 48.6 42.8 – – 0.2 – Other – – –0.3 – – – – – EBITDA1 479.8 382.6 1,407.0 1,034.1 23.1 11.2 57.9 33.2 One-time items 21.6 83.1 48.1 284.3 1.1 8.1 –0.1 14.0 EBITDA pre one-time items (Segment result)1 501.4 465.7 1,455.1 1,318.4 24.2 19.3 57.8 47.2 EBITDA margin pre one-time items (% of sales)1 33.8 30.8 32.6 29.5 18.4 15.7 15.9 13.5 Net operating assets2 7,268.5 8,020.6 293.4 283.8 Segment [...]
[...] income declined by –24.3% to € 85 million (Q3 2012: € 112 million). This was primarily the result of the termination of a licensing agreement owing to the expiration of a patent for the third-party product Avonex® in May 2013. XLS Merck Serono | Key figures € million Q3 – 2013 Q3 – 2012 Change Jan.–Sept. 2013 Jan.–Sept. 2012 Change Total revenues 1,568.1 1,623.0 –3.4% 4,739.5 4,767.0 –0.6% Sales 1,483.0 1,510.6 –1.8% 4,468.2 4,474.3 –0.1% Operating result (EBIT) 274.5 152.3 80.2% 752.2 327.8 129.5% Margin (% of sales) 18.5% 10.1% 16.8% 7.3% EBITDA 479.8 382.6 25.4% 1,407.0 1,034.1 36.1% Margin (% of sales) 32.4% 25.3% 31.5% 23.1% EBITDA pre [...]
[...] Solutions and Bioscience business units remained at the previous year’s level of € 6 million. As a result of price and volume increases, the division’s two largest business units in terms of sales, Lab Solutions and Process Solutions, were able to more than offset the weaker organic sales development of the third business unit, Bioscience. Consequently, notable organic growth was achieved despite weakness in the North American market. This underlines the division’s balanced product portfolio, which successfully compensated for fluctuations in demand in individual market segments in the third quarter of 2013. The Process Solutions business unit, which [...]
[...] 2,751.8 2,841.0 –3.1% 8,353.4 8,338.1 0.2% Sales 2,659.5 2,721.7 –2.3% 8,063.8 8,028.7 0.4% Operating result (EBIT) 481.8 318.1 51.4% 1,346.6 651.9 106.6% Margin (% of sales) 18.1% 11.7% 16.7% 8.1% EBITDA 796.4 661.0 20.5% 2,343.4 1,689.4 38.7% Margin (% of sales) 29.9% 24.3% 29.1% 21.0% EBITDA pre one-time items 830.7 754.2 10.1% 2,458.1 2,175.1 13.0% Margin (% of sales) 31.2% 27.7% 30.5% 27.1% EPS pre one-time items (€) 2.29 1.98 15.7% 6.66 5.56 19.8% Free cash flow 743.8 814.8 –8.7% 1,732.0 1,860.2 –6.9% Merck’s solid business performance in the first half continued in the third quarter of 2013 with total revenues increasing organically by 3.6%. [...]
[...] revenues 406.7 446.7 –9.0% 1,260.5 1,259.5 0.1% Sales 406.5 446.0 –8.9% 1,258.9 1,258.6 – Operating result (EBIT) 176.6 163.7 7.9% 519.3 476.6 9.0% Margin (% of sales) 43.5% 36.7% 41.3% 37.9% EBITDA 202.2 194.5 4.0% 610.6 564.7 8.1% Margin (% of sales) 49.7% 43.6% 48.5% 44.9% EBITDA pre one-time items 196.8 197.3 –0.2% 613.2 553.5 10.8% Margin (% of sales) 48.4% 44.2% 48.7% 44.0% The division’s cost of sales declined by around € –41 million, or –21.5%, to € 149 million (Q3 2012: € 189 million), which was approximately on par with the decrease in sales (€ –40 million). Consequently, gross profit was almost unchanged compared to the previous [...]
